Distinct Phosphoinositide 3-Kinases Mediate Mast Cell Degranulation in Response to G-protein-coupled Versus Fcepsilon RI Receptors*

David A. WindmillerDagger and Jonathan M. Backer§

From the Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461

Received for publication, November 19, 2002, and in revised form, January 6, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphoinositide (PI) 3-kinases are critical regulators of mast cell degranulation. The Class IA PI 3-kinases p85/p110beta and p85/p110delta but not p85/p110alpha are required for antigen-mediated calcium flux in RBL-2H3 cells (Smith, A. J., Surviladze, Z., Gaudet, E. A., Backer, J. M., Mitchell, C. A., and Wilson, B. S. et al., (2001) J. Biol. Chem. 276, 17213-17220). We now examine the role of Class IA PI 3-kinases isoforms in degranulation itself, using a single-cell degranulation assay that measures the binding of fluorescently tagged annexin V to phosphatidylserine in the outer leaflet of the plasma membrane of degranulated mast cells. Consistent with previous data, antibodies against p110delta and p110beta blocked Fcepsilon R1-mediated degranulation in response to Fcepsilon RI ligation. However, antigen-stimulated degranulation was also inhibited by antibodies against p110alpha , despite the fact that these antibodies have no effect on antigen-induced calcium flux. These data suggest that p110alpha mediates a calcium-independent signal during degranulation. In contrast, only p110beta was required for enhancement of antigen-stimulated degranulation by adenosine, which augments mast cell-mediated airway inflammation in asthma. Finally, we examined carbachol-stimulated degranulation in RBL2H3 cells stably expressing the M1 muscarinic receptor (RBL-2H3-M1 cells). Surprisingly, carbachol-stimulated degranulation was blocked by antibody-mediated inhibition of the Class III PI 3-kinase hVPS34 or by titration of its product with FYVE domains. Antibodies against Class IA PI 3-kinases had no effect. These data demonstrate: (a) a calcium-independent role for p110alpha in antigen-stimulated degranulation; (b) a requirement for p110beta in adenosine receptor signaling; and (c) a requirement for hVPS34 during M1 muscarinic receptor signaling. Elucidation of the intersections between these distinct pathways will lead to new insights into mast cell degranulation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mast cells are important cellular mediators of allergic responses in humans (1). Moreover, increased levels of mast cells and mast cell-derived inflammatory mediators are found in brochoalveolar lavage fluid from asthmatics, suggesting a role for mast cells in the etiology of clinical asthma (2-4). Cross-linking of cell surface Fcepsilon RI receptors leads to the release of pre-formed mediators present in mast cell granules, as well as the induction of cytokines and bioactive lipids (5). Release of these inflammatory molecules in the lung is likely to contribute to inflammation and vasoconstriction during asthma. Antigen-mediated degranulation is enhanced by co-stimulation of mast cells with adenosine, which is an important contributor to airway inflammation in asthma (6).

The initial signaling events during antigen-stimulated degranulation have been well studied. Fcepsilon RI cross-linking leads to recruitment and activation of lyn and syk tyrosine kinases, with subsequent phosphorylation of tyrosine residues in the Fcepsilon RI gamma -chain (5, 7). This leads to the recruitment, phosphorylation and activation of phospholipase Cgamma , and generation of inositol trisphosphate and diacylglycerol from the hydrolysis of plasma membrane phosphatidylinositol (4,5)-bisphosphate. Inositol trisphosphate-mediated release of intracellular calcium stores and activation of classical and novel isoforms of protein kinase C (8) are required for the opening of plasma membrane calcium channels. The increase in intracellular calcium levels is critical for degranulation, as evidenced by the fact that thapsigargin or calcium ionophores can induce mast cell degranulation in the absence of additional stimuli.

G-protein-coupled receptors (GPCRs)1 also regulate mast cell degranulation. In bone marrow-derived mast cells and in a cell culture model, the RBL-2H3 basoleukemic line, adenosine can synergistically enhance degranulation in response to FceRI crosslinking, although it is not sufficient to stimulate degranulation (6, 9, 10). Adenosine signaling in RBL-2H3 cells is primarily mediated by the A3 adenosine receptor, a Galpha i-coupled GPCR (9). In addition, Beaven and colleagues (11) demonstrated that stable expression in RBL-2H3 cells of a heterologous GPCR, the M1 muscarinic acetylcholine receptor, leads to carbachol-stimulated degranulation. Carbachol versus antigen stimulation of RBL-2H3-M1 cells lead to similar changes in calcium mobilization and activation of Erk and phospholipase A2 (12-14), although carbachol-stimulated degranulation used PLCbeta rather than PLCgamma to trigger PKC activation and calcium flux (13).

The phosphoinositide 3-kinase inhibitor wortmannin is a potent inhibitor of mast cell degranulation (15), and deletion of the gene for the phosphatidylinositol trisphosphate-phosphatase SHIP markedly enhances mast cell degranulation (16). These data demonstrate that PI 3-kinases are important regulators of antigen-stimulated degranulation. Microinjection of isoform-specific inhibitory antibodies to p110beta and p110delta reduce antigen-stimulated calcium flux and membrane ruffling in RBL-2H3 cells (17). In addition, recent studies on a mouse knockout of the Class IB PI 3-kinase, p110gamma , suggest that p110gamma is important in both FceRI and adenosine-mediated degranulation (18). However, the role of Class IA and Class III PI 3-kinases in degranulation itself has not been directly examined. In this paper, we use specific inhibitory antibodies against Class IA and Class III PI 3-kinases to test the requirement for these enzymes during degranulation. Using a single-cell degranulation assay in RBL-2H3 cells, we show that the three Class IA PI 3-kinases are all required for optimal antigen-stimulated degranulation. In contrast, synergistic enhancement of antigen-stimulated degranulation by adenosine specifically requires p85/p110beta . Surprisingly, carbachol-stimulated degranulation in RBL-2H3-M1 cells does not require Class I PI 3-kinases and instead requires the Class III enzyme hVPS34. The utilization of PKC isozymes in antigen versus carbachol-stimulated degranulation was also different. These data suggest a novel role of hVPS34 in GPCR signaling and highlight the regulatory complexity of ligand-stimulated degranulation in mast cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- RBL-2H3 and RBL-2H3 cells expressing the M1 muscarinic receptor (RBL-2H3-M1) were cultured in Iscove's modified Dulbecco's medium containing 15% fetal bovine serum on Nunc tissue culture dishes or fibronectin-coated coverslips.

Antibodies, cDNA Constructs, and Inhibitors-- Isoform-specific inhibitory antibodies against p110alpha , p110beta , p110delta , and hVPS34 have been described previously (19-21). All antibodies were affinity-purified and concentrated to 4 mg/ml in phosphate-buffered saline. The eGFP-2X-FYVE construct (22) was obtained from Dr Harald Stenmark, The Norwegian Radium Hospital, Norway. Wortmannin was obtained from Sigma, and rottlerin and Go6976 were obtained from Calbiochem.

Microinjections and Transfections-- Cells were microinjected using an Eppendorf 5171/5242 semi-automatic micromanipulator/microinjector as described previously (19). Cells were allowed to recover for 2 h after injection prior to stimulation as described below.

Degranulation Assays-- RBL-2H3 cells were incubated overnight in 0.1 µg/ml anti-DNP IgG. The cells were washed in Hanks' basic salt solution (HBSS) and stimulated for 45 min at 37 °C with HBSS, 1 mM calcium containing 10 ng/ml DNP-albumin. For adenosine experiments, cells were stimulated with 0.5 ng/ml DNP-albumin in the absence or presence of 10 µM adenosine or carrier. Alternatively, RBL-2H3-M1 cells were stimulated for 45 min at 37 °C with HBSS containing 100 µM carbachol or carrier. In each case, the supernatant was removed and brought to 100 mM citrate, pH 4.5, 1 mM 4-methylumbelliferyl-N-acetyl glucosamine (Sigma). After 15 min at 37 °C, the reaction was stopped with 1/10 volume of 200 mM Na2CO3, glycine, pH 10.7, and substrate hydrolysis measured using a fluorescence spectrophotometer (360 excitation/465 emission).

For detection of degranulated cells using annexin V, cells grown on fibronectin-coated coverslips were preloaded as described above, washed in HBSS, and stimulated as described with the additional presence of a 1:10 dilution of Alexa 594 or Alexa 488 annexin V reagent (Molecular Probes, Eugene, OR). The cells were washed, fixed in 3.7% formaldehyde for 10 min at 22 °C, and mounted. Cells were scored for annexin V staining using a Nikon Eclipse 400 upright microscope with a 60 × 1.4 N.A. plan-apo infinity-corrected objective. Each measurement reflects ~100 injected cells per condition, and the data are the mean from three to five separate experiments. When indicated, cells were transfected with LipofectAMINE Plus according to manufacturer's instructions (Invitrogen). Images were acquired using a Cohu 4910 B/W CCD camera with NIH Image 1.62 analysis software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A Single-cell Assay for Mast Cell Degranulation-- We and others (19-21) have previously characterized specific inhibitory antibodies to Class I and Class III PI 3-kinases. To use these reagents to study mast cell degranulation in single cells, we modified a flow cytometry assay developed by Demo et al. (23), in which the binding of fluorescently labeled annexin V is used to identify degranulated cells. As shown in Fig. 1, quiescent anti-DNP IgE-loaded RBL-2H3 cells show no staining with FITC-annexin V (Fig. 1B). In contrast, after stimulation of Fcepsilon RI receptors with DNP-albumin for 45 min, a clear increase in FITC-annexin V staining is seen in most cells (Fig. 1D). To validate the use of annexin V staining as a single-cell assay, we used the percentage of FITC-annexin V-positive cells as a measure of degranulation, and compared it witho degranulation as determined by a biochemical assay of degranulation, the release of beta -hexosaminidase activity. Both assays showed a similar dose response for degranulation in DNP-albumin-stimulated cells (Fig. 1E). In addition, both assays showed similar inhibition by the PI 3-kinase inhibitor wortmannin (Fig. 1F) and by the pan-PKC inhibitor Bisindolmaleimide (data not shown). Thus, the annexin V-based assay accurately reflects ligand-stimulated degranulation of RBL-2H3 cells.


View larger version (71K):
[in this window]
[in a new window]
 
Fig. 1.   A single-cell assay for mast cell degranulation. A-D, RBL-2H3 cells grown on fibronectin-coated coverslips were preloaded with anti-DNP-IgE overnight, then incubated for 45 min at 37 °C with a 1:10 dilution of Alexa 488-annexin V reagent (Molecular Probes) in the absence (A, B) or presence (C, D) of 10 ng/ml DNP-albumin. The cells were then fixed and visualized by phase contrast (A, C) or immunofluorescence (B, D) microscopy. E, RBL-2H3 cells were preloaded overnight with anti-DNP IgE, then stimulated with the indicated concentration of DNP-albumin in the presence of Alexa 488-annexin V for 45 min at 37 °C. Medium from parallel coverslips was assayed for release of beta -hexosaminidase (beta hex) activity or by scoring the percentage of cells that were stained with annexin V. The data are expressed as percentage of maximum and are representative of two separate experiments. F, anti-DNP IgE-loaded cells were incubated in the absence or presence of 100 nM wortmannin for 15 min, then stimulated with DNP-albumin in the presence of Alexa 488-annexin V for 45 min. Degranulation was measured by beta -hexosaminidase assay of the medium or by annexin V staining as above. The data are representative of three separate experiments. BSA, bovine serum albumin.

Role of Class IA PI 3-Kinases during Fcepsilon RI-mediated Degranulation-- It was previously shown that specific inhibition of two isoforms of Class IA PI 3-kinase, p85/p110beta and p85/p110delta , diminishes antigen-stimulated calcium flux and membrane ruffling in RBL-2H3 cells (17). To directly examine their role in degranulation, anti-DNP IgE-loaded RBL-2H3 cells were microinjected with inhibitory antibodies to p110alpha , p110beta , p110delta , and the Class III PI 3-kinase hVPS34. After a recovery period, the cells were stimulated with 10 ng/ml DNP-albumin for 45 min. Whereas microinjection of rabbit IgG or anti-hVPS34 antibodies had no effects on degranulation, microinjection of antibodies against p110alpha , p110beta , and p110gamma inhibited degranulation by 70%, 60%, and 45%, respectively (Fig. 2A).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Degranulation in response to Fcepsilon RI activation. A, RBL-3H3 cells were loaded with anti-DNP IgE overnight, then microinjected with antibodies against p110alpha , p110beta , p110delta , or hVPS34 as indicated. The cells were stimulated with 10 ng/ml albumin-DNP in the presence of Alexa 488-annexin V for 45 min at 37 °C and fixed and stained with Cy3-anti-rabbit antibodies (to detect injected cells). Degranulation was expressed as annexin V-positive injected cells as a percentage of annexin V-positive non-injected cells on the same coverslip. Data are the mean ± S.E. from three experiments. B, RBL-3H3 cells were microinjected with antibodies against p110alpha , p110beta , p110delta , or hVPS34 as indicated. The cells were then stimulated with 0.5 ng/ml DNP-albumin in the absence or presence of 10 µM adenosine for 45 min at 37 °C. All incubations also included Alexa 488-annexin V. Degranulation was measured as described above. Data are expressed as fold increase in the presence of adenosine and are the mean ± S.E. from three experiments.

We also examined the role of these PI 3-kinases in signaling by the adenosine receptor, a physiologically important contributor to airway inflammation and mast cell activation in asthma (6). Adenosine is not sufficient to induce degranulation but can enhance Fcepsilon RI-mediated degranulation in RBL-2H3 cells (9). Anti-DNP IgE-loaded RBL-2H3 cells were microinjected as above and then stimulated with a suboptimal does of DNP-albumin (0.5 ng/ml) in the absence or presence of 10 µM adenosine. In control cells, adenosine caused a 3-4-fold increase in the number of degranulated cells. This was unaffected by microinjection of antibodies against p110alpha , p110delta , or hVPS34 (Fig. 2B). In contrast, the effects of adenosine were markedly attenuated by antibodies against p110beta . These data demonstrate a general requirement for Class IA PI 3-kinase during Fcepsilon RI-mediated degranulation and a specific requirement for p85/p110beta during adenosine-stimulated degranulation.

Carbachol-stimulated Degranulation in RBL-2H3-M1 Cells Requires hVPS34-- The RBL-2H3-M1 line, which expresses the M1 acetylcholine receptor, was developed as a model system to study cholinergic regulation of secretion and neurotransmitter release (11). Carbachol elicits a robust degranulation response in these cells. To examine the role of PI 3-kinases in M1 muscarinic receptor signaling, we microinjected RBL-2H3-M1 cells with inhibitory anti-PI 3-kinase antibodies and stimulated the cells with 100 µM carbachol for 45 min. Unlike antigen-stimulated degranulation, carbachol-stimulated degranulation was unaffected by inhibition of any of the Class I PI 3-kinases (Fig. 3A). Surprisingly, carbachol-stimulated degranulation was markedly reduced by inhibition of the Class III enzyme, hVPS34 (Fig. 3A). To confirm the role of hVPS34 in carbachol-stimulated degranulation, we transiently transfected RBL-2H3 or RBL-2H3-M1 cells with an eGFP-linked construct containing two FYVE domains from hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) (22). Although this construct is useful as a marker for PI(3)P-containing membranes when expressed at low levels, high level overexpression of FYVE domain-containing proteins has been shown to disrupt PI(3)P-mediated signaling, presumably by titration of PI(3)P (24). We therefore used high level expression of the construct to disrupt PI(3)P-dependent signaling. We found that overexpression of the eGFP-FYVE in mast cells had no effect on Fcepsilon RI-mediated degranulation in RBL-2H3 cells, but it inhibited carbachol-stimulated degranulation in the RBL-2H3-M1 cells (Fig. 3B). Thus, both hVPS34 and its lipid product, PI(3)P, are required for carbachol-stimulated degranulation.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Degranulation in response to M1 muscarinic receptor activation. A, RBL-3H3-M1 cells were microinjected with antibodies against p110alpha , p110beta , p110delta , or hVPS34 as indicated. The cells were then stimulated with 100 µM carbachol in the presence of Alexa 488-annexin V for 45 min at 37 °C, and degranulation was determined as described in the legend to Fig. 2. Data are the mean ± S.E. from three experiments. B, RBL-3H3-M1 cells were transfected with expression plasmids for either eGFP or eGFP-FYVE as indicated. After 6 h, the cells were stimulated with 100 µM carbachol in the presence of Alexa 594-annexin V for 45 min at 37 °C. Degranulation in eGFP-labeled cells was determined as described above and expressed as a percentage of degranulation in untransfected cells. Data are the mean ± S.E. from three experiments.

Differential Utilization of PKC Isoforms in Fcepsilon RI Versus M1-mediated Degranulation-- To further characterize differential signaling during antigen versus carbachol-stimulated degranulation, we examined the requirement for PKCbeta and PKCdelta . These isoforms have previously been shown to be stimulatory for degranulation in RBL-2H3 cells in response to antigen (8). We found that the PKCdelta inhibitor rottlerin had similar inhibitory effects on both antigen and carbachol-stimulated degranulation, with IC50 values of ~3-10 µM in the two cell lines (Fig. 4B). In contrast, the PKCalpha /beta inhibitor Go6976 potently inhibited antigen-stimulated degranulation in RBL-2H3 cells (IC50 10 nm), but had no effect on carbachol-stimulated degranulation in the RBL-2H3-M1 cells (Fig. 4A). These data show that the utilization of both PKC and PI 3-kinase isoforms is different in carbachol versus antigen-stimulated degranulation.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   Differential utilization of PKC isoforms in antigen versus carbachol-stimulated cells. A, anti-DNP-IgE-loaded RBL-2H3 cells (left panel) and RBL-2H3-M1 cells (right panel) were treated with the indicated concentrations of Go6976 for 1 h. The cells were then stimulated with 10 ng/ml DNP-albumin (left panel) or 500 µM carbachol (right panel), and degranulation was measured by assaying the media for beta -hexosaminidase release. Data are the mean ± S.E. from three experiments. B, anti-DNP-IgE-loaded RBL-2H3 cells (left panel) and RBL-2H3-M1 cells (right panel) were treated with the indicated concentrations of rottlerin for 1 h. The cells were then stimulated with 10 ng/ml DNP-albumin (left panel) or 500 µM carbachol (right panel), and degranulation was measured by assaying the media for beta -hexosaminidase release. Data are the mean ± S.E. from three experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this report we have used well characterized isoform-specific anti-PI 3-kinase antibodies (19-21), in conjunction with a single-cell assay for degranulation, to identify the roles of distinct PI 3-kinases during mast cell degranulation. The assay is based on a previously published flow cytometry assay (23), which used fluorescently labeled annexin V to quantitate the increase in exofacial phosphatidylserine that occurs in the plasma membrane of degranulated cells. A similar increase in exofacial phosphatidylserine occurs in apoptotic cells, and fluorescent annexin V is a commonly used assay for apoptosis (25). In the single cell assay presented here, degranulation is expressed as the percentage of annexin V-positive cells per field. The dose-response curve for antigen-stimulated degranulation using this assay correlates well with biochemical assays for degranulation and shows similar sensitivity to wortmannin. This assay provides a useful adjunct to previous single-cell studies in RBL-2H3 cells, which focused on calcium flux and membrane ruffling (17).

The importance of examining degranulation itself, as opposed to degranulation-related events, is shown in the experiments on the role of Class IA PI 3-kinases during antigen-stimulated degranulation. Antigen-stimulated calcium flux has previously been shown to require p85/p110beta and p85/p110delta but not p85/p110alpha (17). The role of these enzymes in calcium flux is likely to be mediated by the potentiation of PLCgamma activation by phosphatidylinositol trisphosphate, either through Tec-family tyrosine kinases (26), Vav1 (27), or via direct effects on PLCgamma (28, 29). A direct effect of phosphatidylinositol trisphosphate on calcium uptake has also been demonstrated (30). However, an additional calcium-independent role of PI 3-kinases has been suggested by the fact that thapsigargin or calcium ionophore-mediated degranulation is still sensitive to PI 3-kinase inhibitors (15, 31-33). Our data show that p85/p110alpha is required for degranulation despite the fact that it is not required for antigen-stimulated calcium flux in RBL-2H3 cells (17). This suggests that p85/p110alpha is a candidate for the wortmannin-sensitive, calcium-independent factor in antigen-stimulated degranulation.

Our experiments also reveal a role for the p85/p110beta PI 3-kinase during adenosine-stimulated degranulation in cells treated with sub-optimal doses of antigen. The specific requirement for p85/p110beta in signaling by this Galpha i-coupled receptor is consistent with reports that p110beta is activated by beta gamma subunits from trimeric G-proteins (34, 35) and is required for lysophosphatidic acid-mediated signaling (36). In addition to p110beta , p110gamma is also required for adenosine secretion by mast cells and adenosine-mediated autocrine stimulation of degranulation in antigen-stimulated mast cells (18). The coordination of these two Gbeta gamma -regulated PI 3-kinases during degranulation, and their potentially different downstream effectors, will be a subject of interest for future studies.

We also studied degranulation in a heterologous system, the RBL-2H3-M1 cell line (11), which expresses the Galpha q-coupled M1 muscarinic receptor. Previous studies have shown that carbachol-stimulated degranulation in these cells is different in several respects from FceRI-stimulated degranulation, for example with regard to the role of Src-family tyrosine kinases (37). Similarly, we find that inhibitors of PKCalpha /beta block degranulation in antigen-stimulated RBL-2H3 cells but not carbachol-stimulated RBL-2H3-M1 cells. Even given these differences, the requirement for hVPS34 during carbachol-stimulated degranulation of RBL-2H3-M1 cells is a surprising finding. The best documented roles for hVPS34 in mammalian cells are in the regulation of traffic through the endocytic or phagocytic systems (19, 38-43), and during the sorting of newly synthesized membrane proteins in polarized cells (44). These reports are consistent with the well characterized role of VPS34p in vesicular trafficking in yeast (45). However, a role for hVPS34 during regulated secretion has not been demonstrated. It seems unlikely that hVPS34 is involved in degranulation at the level of granule fusion, since it would then also be required for degranulation in response to Fcepsilon RI receptor activation. Instead, our data suggest a novel role for hVPS34 in Galpha q-coupled receptor signaling.

How might hVPS34 modulate signaling from the M1 acetylcholine receptor? hVPS34 signals via the production of PI(3)P and the recruitment and/or activation of proteins containing FYVE or PX domains, which specifically bind to PI(3)P (46-49). In both mammalian cells and yeast, hVPS34 is targeting to membranes along with an associated protein kinase (VPS15/p150) (40, 45, 50); in mammalian cells the Rab5 GTPase also regulates hVPS34 targeting to endosomes (38, 40). Disruption of hVPS34 alters the post-endocytic trafficking of cell surface receptors (19, 41) and therefore could affect the post-endocytic sorting of carbachol-stimulated M1 receptors. This could alter the signaling properties of the receptor, as has been suggested in the beta -adrenergic receptor system (51). Alternatively, a recently described RGS protein, RGS-PX1, is a Galpha s-specific GAP that contains a PX domain (52); such a protein could provide a mechanism for the regulation of Galpha s-coupled receptors by hVPS34. It is possible that PX- or FYVE-domain-containing RGS proteins might exist for Galpha q-coupled receptors as well. Finally, it is possible that hVPS34 is a direct target of activated M1 receptors. However, we have so far been unable to detect changes in hVPS34 activity in immunoprecipitates from carbachol-stimulated RBL-2H3 cells (data not shown).

In summary, we have used a single cell assay for mast cell degranulation to study the role of different PI 3-kinases in this process. We find a general role for Class IA PI 3-kinases in response to antigen-stimulated degranulation and a specific requirement for p85/p110beta during adenosine receptor-Fcepsilon RI receptor synergy. We also find an unexpected requirement for hVPS34 in carbachol-stimulated degranulation. These latter data suggest an unappreciated role for hVPS34 in signaling by Galpha q-coupled receptors. It will be important to determine whether hVPS34 also plays a role in signaling by other G-protein-coupled receptors.

    ACKNOWLEDGEMENT

We thank Dr. Bart Vanhaesebroeck, Ludwig Institute for Cancer Research, for anti-p110delta antibodies.

    FOOTNOTES

* This work was supported by a grant from the Sandler Foundation for Asthma Research (to J. M. B.) and by National Institutes of Health Training Grant T32 DK07513 (to D. A. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Current address: Integrated Dept. of Immunology, National Jewish Center, Denver, CO 80206.

§ To whom correspondence should be addressed: Dept. of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Tel.: 718-430-2153; Fax: 718-430-3749; E-mail: Backer@aecom.yu.edu.

Published, JBC Papers in Press, January 14, 2003, DOI 10.1074/jbc.M211787200

    ABBREVIATIONS

The abbreviations used are: GPCR, G-protein-coupled receptor; DNP, dinitrophenol; eGFP, enhanced green fluorescent protein; FITC, fluorescein isothyocyanate; FYVE domain, Fab1/YOTB/Vac1p/EEA1-homology domain; PI(3)P, phosphatidylinositol 3-phosphate; PLC, phospholipase C; PKC, protein kinase C; PX domain, Phox homology domain; RGS, regulator of G-protein signaling; PI, phosphoinositide; HBSS, Hanks' basic salt solution.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Forsythe, P., and Ennis, M. (1999) Inflamm. Res. 48, 301-307[CrossRef][Medline] [Order article via Infotrieve]
2. Olsson, N., Rak, S., and Nilsson, G. (2000) J. Allergy Clin. Immunol. 105, 455-461[Medline] [Order article via Infotrieve]
3. Gibson, P. G., Saltos, N., and Borgas, T. (2000) J. Allergy Clin. Immunol. 105, 752-759[CrossRef][Medline] [Order article via Infotrieve]
4. Bingham, C. O., and Austen, K. F. (2000) J. Allergy Clin. Immunol. 105, S527-S534[Medline] [Order article via Infotrieve]
5. Reischl, I. G., Coward, W. R., and Church, M. K. (1999) Biochem. Pharmacol. 58, 1841-1850[CrossRef][Medline] [Order article via Infotrieve]
6. Holgate, S. T., Church, M. K., and Polosa, R. (1991) Ann. N. Y. Acad. Sci. 629, 227-236[Medline] [Order article via Infotrieve]
7. Turner, H., and Kinet, J. P. (1999) Nature 402, B24-B30[CrossRef][Medline] [Order article via Infotrieve]
8. Ozawa, K., Szallasi, Z., Kazanietz, M. G., Blumberg, P. M., Mischak, H., Mushinski, J. F., and Beaven, M. A. (1993) J. Biol. Chem. 268, 1749-1756[Abstract/Free Full Text]
9. Ramkumar, V., Stiles, G. L., Beaven, M. A., and Ali, H. (1993) J. Biol. Chem. 268, 16887-16890[Abstract/Free Full Text]
10. Marquardt, D. L., Parker, C. W., and Sullivan, T. J. (1978) J. Immunol. 120, 871-878[Medline] [Order article via Infotrieve]
11. Jones, S. V., Choi, O. H., and Beaven, M. A. (1991) FEBS Lett. 289, 47-50[CrossRef][Medline] [Order article via Infotrieve]
12. Hirasawa, N., Santini, F., and Beaven, M. A. (1995) J. Immunol. 154, 5391-5402[Abstract/Free Full Text]
13. Choi, O. H., Lee, J. H., Kassessinoff, T., Cunha-Melo, J. R., Jones, S. V., and Beaven, M. A. (1993) J. Immunol. 151, 5586-5595[Abstract/Free Full Text]
14. Offermanns, S., Jones, S. V., Bombien, E., and Schultz, G. (1994) J. Immunol. 152, 250-261[Abstract/Free Full Text]
15. Kitani, S., Teshima, R., Morita, Y., Ito, K., Matsuda, Y., and Nonomura, Y. (1992) Biochem. Biophys. Res. Commun. 183, 48-54[Medline] [Order article via Infotrieve]
16. Huber, M., Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K., and Krystal, G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11330-11335[Abstract/Free Full Text]
17. Smith, A. J., Surviladze, Z., Gaudet, E. A., Backer, J. M., Mitchell, C. A., and Wilson, B. S. (2001) J. Biol. Chem. 276, 17213-17220[Abstract/Free Full Text]
18. Laffargue, M., Calvez, R., Finan, P., Trifilieff, A., Barbier, M., Altruda, F., Hirsch, E., and Wymann, M. P. (2002) Immunity 16, 441-451[Medline] [Order article via Infotrieve]
19. Siddhanta, U., McIlroy, J., Shah, A., Zhang, Y. T., and Backer, J. M. (1998) J. Cell Biol. 143, 1647-1659[Abstract/Free Full Text]
20. Hill, K., Welti, S., Yu, J. H., Murray, J. T., Yip, S. C., Condeelis, J. S., Segall, J. E., and Backer, J. M. (2000) J. Biol. Chem. 275, 3741-3744[Abstract/Free Full Text]
21. Vanhaesebroeck, B., Jones, G. E., Allen, W. E., Zicha, D., Hooshmand-Rad, R., Sawyer, C., Wells, C., Waterfield, M. D., and Ridley, A. J. (1999) Nat. Cell Biol. 1, 69-71[CrossRef][Medline] [Order article via Infotrieve]
22. Gillooly, D. J., Morrow, I. C., Lindsay, M., Gould, R., Bryant, N. J., Gaullier, J. M., Parton, R. G., and Stenmark, H. (2000) EMBO J. 19, 4577-4588[Abstract/Free Full Text]
23. Demo, S. D., Masuda, E., Rossi, A. B., Throndset, B. T., Gerard, A. L., Chan, E. H., Armstrong, R. J., Fox, B. P., Lorens, J. B., Payan, D. G., Scheller, R. H., and Fisher, J. M. (1999) Cytometry 36, 340-348[CrossRef][Medline] [Order article via Infotrieve]
24. Patki, V., Lawe, D. C., Corvera, S., Virbasius, J. V., and Chawla, A. (1998) Nature 394, 433-434[CrossRef][Medline] [Order article via Infotrieve]
25. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. (1995) J. Immunol. Methods 184, 39-51[CrossRef][Medline] [Order article via Infotrieve]
26. Scharenberg, A. M., El-Hillal, O., Fruman, D. A., Beitz, L. O., Li, Z., Lin, S., Gout, I., Cantley, L. C., Rawlings, D. J., and Kinet, J. P. (1998) EMBO J. 17, 1961-1972[Free Full Text]
27. Manetz, T. S., Gonzalez-Espinosa, C., Arudchandran, R., Xirasagar, S., Tybulewicz, V., and Rivera, J. (2001) Mol. Cell. Biol. 21, 3763-3774[Abstract/Free Full Text]
28. Barker, S. A., Lujan, D., and Wilson, B. S. (1999) J. Leukocyte Biol. 65, 321-329[Abstract]
29. Bae, Y. S., Cantley, L. G., Chen, C. S., Kim, S. R., Kwon, K. S., and Rhee, S. G. (1998) J. Biol. Chem. 273, 4465-4469[Abstract/Free Full Text]
30. Ching, T. T., Hsu, A. L., Johnson, A. J., and Chen, C. S. (2001) J. Biol. Chem. 276, 14814-14820[Abstract/Free Full Text]
31. Huber, M., Hughes, M. R., and Krystal, G. (2000) J. Immunol. 165, 124-133[Abstract/Free Full Text]
32. Hirasawa, N., Sato, Y., Yomogida, S., Mue, S., and Ohuchi, K. (1997) Cell. Signal. 9, 305-310[CrossRef][Medline] [Order article via Infotrieve]
33. Marquardt, D. L., Alongi, J. L., and Walker, L. L. (1996) J. Immunol. 156, 1942-1945[Abstract]
34. Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S., Fukui, Y., Ui, M., Hazeki, O., and Katada, T. (1997) J. Biol. Chem. 272, 24252-24256[Abstract/Free Full Text]
35. Murga, C., Fukuhara, S., and Gutkind, J. S. (2000) J. Biol. Chem. 275, 12069-12073[Abstract/Free Full Text]
36. Roche, S., Downward, J., Raynal, P., and Courtneidge, S. A. (1998) Mol. Cell. Biol. 18, 7119-7129[Abstract/Free Full Text]
37. Hirasawa, N., Scharenberg, A., Yamamura, H., Beaven, M. A., and Kinet, J. P. (1995) J. Biol. Chem. 270, 10960-10967[Abstract/Free Full Text]
38. Christoforidis, S., Miaczynska, M., Ashman, K., Wilm, M., Zhao, L., Yip, S.-C., Waterfield, M. D., Backer, J. M., and Zerial, M. (1999) Nat. Cell Biol. 1, 249-252[CrossRef][Medline] [Order article via Infotrieve]
39. Nielsen, E., Severin, F., Backer, J. M., Hyman, A. A., and Zerial, M. (1999) Nat. Cell Biol. 1, 376-382[CrossRef][Medline] [Order article via Infotrieve]
40. Murray, J. T., Panaretou, C., Stenmark, H., Miaczynska, M., and Backer, J. M. (2002) Traffic 3, 416-427[CrossRef][Medline] [Order article via Infotrieve]
41. Futter, C. E., Collinson, L. M., Backer, J. M., and Hopkins, C. R. (2001) J. Cell Biol. 155, 1251-1264[Abstract/Free Full Text]
42. Vieira, O. V., Botelho, R. J., Rameh, L., Brachmann, S. M., Matsuo, T., Davidson, H. W., Schreiber, A., Backer, J. M., Cantley, L. C., and Grinstein, S. (2001) J. Cell Biol. 155, 19-25[Abstract/Free Full Text]
43. Fratti, R. A., Backer, J. M., Gruenberg, J., Corvera, S., and Deretic, V. (2001) J. Cell Biol. 154, 631-644[Abstract/Free Full Text]
44. Tuma, P. L., Nyasae, L. K., Backer, J. M., and Hubbard, A. L. (2001) J. Cell Biol. 154, 1197-1208[Abstract/Free Full Text]
45. Stack, J. H., Herman, P. K., Schu, P. V., and Emr, S. D. (1993) EMBO J. 12, 2195-2204[Abstract]
46. Stenmark, H., and Aasland, R. (1999) J. Cell Sci. 112, 4175-4183[Abstract/Free Full Text]
47. Simonsen, A., Wurmser, A. E., Emr, S. D., and Stenmark, H. (2001) Curr. Opin. Cell Biol. 13, 485-492[CrossRef][Medline] [Order article via Infotrieve]
48. Clague, M. J., and Urbe, S. (2001) J. Cell Sci. 114, 3075-3081[Abstract/Free Full Text]
49. Ellson, C. D., Andrews, S., Stephens, L. R., and Hawkins, P. T. (2002) J. Cell Sci. 115, 1099-1105[Abstract/Free Full Text]
50. Panaretou, C., Domin, J., Cockcroft, S., and Waterfield, M. D. (1997) J. Biol. Chem. 272, 2477-2485[Abstract/Free Full Text]
51. Hall, R. A., Premont, R. T., and Lefkowitz, R. J. (1999) J. Cell Biol. 145, 927-932[Free Full Text]
52. Zheng, B., Ma, Y. C., Ostrom, R. S., Lavoie, C., Gill, G. N., Insel, P. A., Huang, X. Y., and Farquhar, M. G. (2001) Science 294, 1939-1942[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.